10/9/2013

Biotechnology company BioTime has begun pre-approval testing of a wound dressing based on cross-linked thiol-modified hyaluronan and thiol-modified gelatin. The product maintains a moist wound bed, and a biodegradable matrix serves as a scaffold for cellular infiltration and capillary growth. If approved, the product may provide a foundation for bioactive wound care products that deliver biological factors or cells.

Related Summaries